Invesco · 2005-06-23 成立 · 规模、费率、NAV、资金流、完整持仓和风险收益使用各自可追溯公开源。
| 日期 | 估算净流 | 申购 / 销售 | 赎回 | 净资产 | 口径 |
|---|---|---|---|---|---|
| 2026-07-31 | +$91,489 | — | — | $277.9M | 每日估算 |
| 2026-07-30 | -$2.3M | — | — | $277.9M | 每日估算 |
| 2026-07-27 | +$5.6M | — | — | $282.4M | 每日估算 |
| 2026-07-26 | -$3.4M | — | — | $277.9M | 每日估算 |
| 2026-04-30 | +$18,195 | $2.4M | $2.4M | $247.4M |
| 持仓 | 资产类别 | 数量 | 市值 | 权重 |
|---|---|---|---|---|
Invesco Private Prime Fund Invesco Private Prime Fund | STIV | 27,001,924 | $27.0M | 10.92% |
United Therapeutics Corp. United Therapeutics Corp. | EC | 27,212 | $15.5M | 6.28% |
Illumina, Inc. Illumina, Inc. | EC | 104,832 | $13.3M | 5.37% |
Biogen Inc. Biogen Inc. |
行情与风险截至 2026-07-30；NAV 的发布时间可能和交易所收盘错位。完整持仓是延迟监管披露，不代表当前盘中组合。
已使用：nasdaq_etf_screener、yahoo_chart、yahoo_quote_summary、sec_nport。缺口标记：nav_timestamp_unverified、category_reclassified_by_current_taxonomy。
| SEC 月度 |
| 2026-03-31 | -$5.4M | $0 | $5.4M | — | SEC 月度 |
| 2026-02-28 | -$2.5M | $0 | $2.5M | — | SEC 月度 |
| EC |
| 66,025 |
| $12.5M |
| 5.05% |
Incyte Corp. Incyte Corp. | EC | 127,499 | $12.1M | 4.91% |
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. | EC | 38,706 | $12.0M | 4.84% |
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. | EC | 16,684 | $11.8M | 4.77% |
Amgen Inc. Amgen Inc. | EC | 33,651 | $11.7M | 4.71% |
Gilead Sciences, Inc. Gilead Sciences, Inc. | EC | 87,264 | $11.4M | 4.62% |
Invesco Private Government Fund Invesco Private Government Fund | STIV | 10,392,972 | $10.4M | 4.20% |
BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals, Inc. | EC | 923,458 | $8.5M | 3.42% |
Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. | EC | 290,513 | $8.2M | 3.30% |
Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. | EC | 110,374 | $8.1M | 3.28% |
Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc. | EC | 80,415 | $8.0M | 3.22% |
TG Therapeutics, Inc. TG Therapeutics, Inc. | EC | 230,335 | $7.8M | 3.15% |
Royalty Pharma PLC, Class A Royalty Pharma PLC, Class A | EC | 154,791 | $7.8M | 3.13% |
CareDx, Inc. CareDx, Inc. | EC | 365,065 | $7.6M | 3.07% |
Neurocrine Biosciences, Inc. Neurocrine Biosciences, Inc. | EC | 53,660 | $7.1M | 2.86% |
Exelixis, Inc. Exelixis, Inc. | EC | 155,682 | $6.9M | 2.80% |
Bio-Techne Corp. Bio-Techne Corp. | EC | 122,004 | $6.7M | 2.73% |
PTC Therapeutics, Inc. PTC Therapeutics, Inc. | EC | 101,877 | $6.6M | 2.68% |
Veracyte, Inc. Veracyte, Inc. | EC | 196,903 | $6.5M | 2.62% |
Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals Inc. | EC | 285,787 | $6.4M | 2.59% |
Vericel Corp. Vericel Corp. | EC | 183,726 | $6.4M | 2.58% |
Halozyme Therapeutics, Inc. Halozyme Therapeutics, Inc. | EC | 99,880 | $6.4M | 2.57% |
Repligen Corp. Repligen Corp. | EC | 52,183 | $6.2M | 2.50% |
Theravance Biopharma Inc. Theravance Biopharma Inc. | EC | 368,704 | $6.2M | 2.49% |
Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. | EC | 82,240 | $6.1M | 2.49% |
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. | EC | 112,225 | $6.1M | 2.45% |
Collegium Pharmaceutical, Inc. Collegium Pharmaceutical, Inc. | EC | 155,578 | $5.2M | 2.12% |
Qiagen N.V. Qiagen N.V. | EC | 144,898 | $5.0M | 2.03% |
MannKind Corp. MannKind Corp. | EC | 1,268,504 | $3.6M | 1.45% |
Invesco Government & Agency Portfolio, Institutional Class Invesco Government & Agency Portfolio, Institutional Class | STIV | 146,277 | $146,277 | 0.06% |